This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PTC Therapeutics Announces That Stuart W. Peltz, Ph.D., CEO Is The Recipient Of The 2014 Dr. Sol J. Barer Award For Vision, Innovation And Leadership

SOUTH PLAINFIELD, N.J., Jan. 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its founder and Chief Executive Officer, Stuart W. Peltz, Ph.D. has been awarded the 2014 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named for Sol J. Barer, Ph.D., founder and former Chairman and Chief Executive Officer of Celgene Corporation of Summit, N.J., the award recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.

(Logo: )

"It is an honor to receive an award named for someone who has accomplished so much for the industry and epitomizes the elements of a successful leader," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics, Inc. "I am grateful for this honor."

Dr. Barer, the former Chairman of Celgene Corporation and a past Chairman of BioNJ, will present the award to Dr. Peltz during ceremonies celebrating BioNJ's 21st Annual Dinner Meeting and Networking Event, which will be held today from 4:30 p.m. to 10:00 p.m. at the Hilton East Brunswick.

"Known for his pioneering research into RNA biology while at the Department of Molecular Genetics and Microbiology at the Robert Wood Johnson Medical School, Rutgers University, Dr. Peltz recognized the potential of post transcriptional mechanisms to advance medical science and help patients in need," said Dr. Barer.

"Dr. Peltz's groundbreaking research has informed the development of new therapeutic options for a wide-range of disorders," said Francois Nader, M.D., President and CEO of NPS Pharmaceuticals of Bedminster and Chairman of the BioNJ Board of Trustees. "His passion for scientific innovation exemplifies the spirit of the Dr. Sol J. Barer Award and the BioNJ Board of Trustees is proud to present Dr. Peltz with this well-deserved honor."

ABOUT THE DR. SOL J. BARER AWARD:The Dr. Sol J. Barer Award for Vision, Innovation, and Leadership was established by the BioNJ Board of Trustees in March 2008 in an effort to recognize the outstanding research and business leaders who have made and continue to make significant contributions to the growth of the biosciences in New Jersey and around the world. The honoree is voted on by the BioNJ Board of Trustees from a recommendation based on nominations received by the Nominating Committee. The award is named for Sol J. Barer, Ph.D., who founded the biotechnology group at Celanese that was subsequently spun out to form Celgene, currently one of the world's largest biotechnology companies.

ABOUT PTC THERAPEUTICS, INC.:PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website

SOURCE PTC Therapeutics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.66 -0.09%
FB $118.58 0.85%
GOOG $698.30 0.76%
TSLA $241.82 0.44%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs